Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels - PubMed (original) (raw)

Randomized Controlled Trial

. 2017 Jan;41(1):179-186.

doi: 10.1111/acer.13272. Epub 2016 Dec 26.

Affiliations

Randomized Controlled Trial

Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels

Katie Witkiewitz et al. Alcohol Clin Exp Res. 2017 Jan.

Abstract

Background: Alcohol use disorder (AUD) is a highly prevalent public health problem associated with considerable individual and societal costs. Abstinence from alcohol is the most widely accepted target of treatment for AUD, but it severely limits treatment options and could deter individuals who prefer to reduce their drinking from seeking treatment. Clinical validation of reduced alcohol consumption as the primary outcome of alcohol clinical trials is critical for expanding treatment options. One potentially useful measure of alcohol treatment outcome is a reduction in the World Health Organization (WHO, International Guide for Monitoring Alcohol Consumption and Related Harm. Geneva, Switzerland, 2000) risk levels of alcohol use (very high risk, high risk, moderate risk, and low risk). For example, a 2-shift reduction in WHO risk levels (e.g., high risk to low risk) has been used by the European Medicines Agency (2010, Guideline on the Development of Medicinal Products for the Treatment of Alcohol Dependence. UK) to evaluate nalmefene as a treatment for alcohol dependence (AD; Mann et al. 2013, Biol Psychiatry 73, 706-13).

Methods: The current study was a secondary data analysis of the COMBINE study (n = 1,383; Anton et al., ) to examine the association between reductions in WHO risk levels and reductions in alcohol-related consequences and mental health symptoms during and following treatment in patients with AD.

Results: Any reduction in WHO risk drinking level during treatment was associated with significantly fewer alcohol-related consequences and improved mental health at the end of treatment and for up to 1 year posttreatment. A greater reduction in WHO risk drinking level predicted a greater reduction in consequences and greater improvements in mental health.

Conclusions: Changes in WHO risk levels appear to be a valid end point for alcohol clinical trials. Based on the current findings, reductions in WHO risk drinking levels during treatment reflect meaningful reductions in alcohol-related consequences and improved functioning.

Keywords: Alcohol Dependence; Alcohol Treatment Outcomes; Harm Reduction; Reduced Alcohol Consumption; World Health Organization Risk Drinking Levels.

Copyright © 2016 by the Research Society on Alcoholism.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Histogram (count) of individuals who had an increase, no change, or decrease in WHO risk level from baseline to the end of treatment.

Figure 2

Figure 2

Average Drinker Inventory of Consequences (DrInC) total scores by change in WHO risk level from baseline (solid line) to the end of treatment and posttreatment (dashed lines). Vertical bars indicate 95% confidence intervals (CIs). n = number of participants with data available for analysis within each level of WHO risk change. d = Cohen's d effect size, computed as the difference in means from baseline to follow‐up within each level of WHO risk change divided by the standard deviation at baseline within the same level of WHO risk change. All means and 95% CIs (baseline and follow‐up) were estimated using linear regression and controlled for age at baseline, gender, race, education, body mass index at baseline, and smoker status at baseline; follow‐up estimates also controlled for baseline values of the dependent variable and baseline WHO risk level. All control variables were grand‐mean‐centered.

Figure 3

Figure 3

Average 12‐item Short Form Health Survey (SF‐12) Mental Health Composite Scores by change in WHO risk level from baseline (solid line) to the end of treatment and posttreatment (dashed lines). Vertical bars indicate 95% confidence intervals (CIs). n = number of participants with data available for analysis within each level of WHO risk change. d = Cohen's d effect size, computed as the difference in means from baseline to follow‐up within each level of WHO risk change divided by the standard deviation at baseline within the same level of WHO risk change. All means and 95% CIs (baseline and follow‐up) were estimated using linear regression and controlled for age at baseline, gender, race, education, body mass index at baseline, and smoker status at baseline; follow‐up estimates also controlled for baseline values of the dependent variable and baseline WHO risk level. All control variables were grand‐mean‐centered.

Comment in

Similar articles

Cited by

References

    1. Aldridge A, Zarkin GA, Dowd W, Bray JW (2016) The relationship between end of treatment alcohol use and subsequent health care costs: do heavy drinking days predict higher health care costs? Alcohol Clin Exp Res 40:1122–1128. - PMC - PubMed
    1. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295:2003–2017. - PubMed
    1. Aubin H‐J, Daeppen J‐B (2013) Emerging pharmacotherapies for alcohol dependence: a systematic review focusing on reduction in consumption. Drug Alcohol Depend 133:15–29. - PubMed
    1. Aubin H‐J, Reimer J, Nutt DJ, Bladström A, Torup L, François C, Chick J (2015) Clinical relevance of as‐needed treatment with nalmefene in alcohol‐dependent patients. Eur Addict Res 21:160–168. - PubMed
    1. Bouchery EE, Harwood HJ, Sacks JJ, Simon CJ, Brewer RD (2011) Economic costs of excessive alcohol consumption in the US, 2006. Am J Prev Med 41:516–524. - PubMed

Publication types

MeSH terms

Grants and funding

LinkOut - more resources